Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease

被引：1
|
作者：
Liam, Christopher Chin Keong [1 ,2 ]
Boo, Yang Liang [1 ,2 ]
Chong, Siew Lian [1 ]
Sathar, Jameela [1 ]
Ong, Tee Chuan [1 ]
Tan, Sen Mui [1 ]
机构：
[1] Hosp Ampang, Dept Haematol, Jalan Mewah Utama, Ampang 68000, Selangor, Malaysia
[2] Hosp Sultanah Aminah, Dept Internal Med, Hematol Unit, Johor Baharu, Malaysia
来源：
BLOOD RESEARCH | 2022年 / 57卷 / 02期
关键词：
TERM-FOLLOW-UP; INTENSITY CHEMOTHERAPY; ADULT PATIENTS; THERAPY; SINGLE; IMATINIB;
D O I：
10.5045/br.2022.2020305
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：158 / +
页数：4
相关论文
共 50 条
  • [1] Characteristics of Philadelphia-positive acute lymphocytic leukemia (Ph+ ALL) in the elderly.
    Coso, D
    Cazin, B
    Thomas, X
    Boiron, JM
    Huguet, F
    Zérazhi, H
    Vernant, JP
    Dombret, H
    Bilhou-Nabera, C
    Charrin, C
    Boucheix, C
    Sebban, C
    Lhéritier, V
    Delannoy, A
    Fière, D
    BLOOD, 2001, 98 (11) : 319A - 319A
  • [2] Acute lymphoblastic leukemia Philadelphia-positive
    Delannoy, Andre
    HEMATOLOGIE, 2006, 12 : 26 - 31
  • [3] Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Wassmann, B
    Pfeifer, H
    Stadler, M
    Bornhäuser, M
    Bug, G
    Scheuring, UJ
    Brück, P
    Stelljes, M
    Schwerdtfeger, R
    Basara, N
    Perz, J
    Bunjes, D
    Ledderose, G
    Mahlberg, R
    Binckebanck, A
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2005, 106 (02) : 458 - 463
  • [4] Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
    Santos, Fabio P. S.
    O'Brien, Susan
    Thomas, Deborah A.
    Cortes, Jorge
    Faderl, Stefan
    Jorgensen, Jeffrey L.
    Garris, Rebecca
    Koller, Charles
    Kebriaei, Partow
    Ferrajoli, Alessandra
    Kantarjian, Hagop
    Ravandi, Farhad
    BLOOD, 2009, 114 (22) : 408 - 409
  • [5] Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Wassmann, Barbara
    Pfeifer, Heike
    Goekbuget, Nicola
    Beelen, Dietrich W.
    Beck, Joachim
    Stelljes, Matthias
    Bornhaeuser, Martin
    Reichle, Albrecht
    Perz, Jolanta
    Haas, Rainer
    Ganser, Arnold
    Schmid, Mathias
    Kanz, Lothar
    Lenz, Georg
    Kaufmann, Martin
    Binckebanck, Anja
    Brueck, Patrick
    Reutzel, Regina
    Gschaidmeier, Harald
    Schwartz, Stefan
    Hoelzer, Dieter
    Ottmann, Oliver G.
    BLOOD, 2006, 108 (05) : 1469 - 1477
  • [6] HETEROGENEITY OF CHROMOSOME-22 BREAKPOINT IN PHILADELPHIA-POSITIVE (PH+) ACUTE LYMPHOCYTIC-LEUKEMIA
    ERIKSON, J
    GRIFFIN, CA
    ARRUSHDI, A
    VALTIERI, M
    HOXIE, J
    FINAN, J
    EMANUEL, BS
    ROVERA, G
    NOWELL, PC
    CROCE, CM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (06) : 1807 - 1811
  • [7] Constitutive NF-κB/Rel activation in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)
    Munzert, G
    Kirchner, D
    Ottmann, O
    Bergmann, L
    Schmid, RM
    LEUKEMIA & LYMPHOMA, 2004, 45 (06) : 1181 - 1184
  • [8] Quantification of the Minimal Residual Disease in Pediatric Philadelphia-Positive Acute Lymphoblastic Leukemia
    Ferri, Cristian
    Riccheri, Cecilia
    Bietti, Julieta
    Cedola, Alejandra
    Bianchini, Michele
    Alberto Aversa, Luis
    Pennesi, Sandra
    Belli, Carolina
    Milone, Gustavo
    Larripa, Irene B.
    BLOOD, 2014, 124 (21)
  • [9] Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia
    Ganzel, Chezi
    Kharit, Mira
    Duksin, Chen
    Rowe, Jacob M.
    HAEMATOLOGICA, 2018, 103 (10) : E489 - E490
  • [10] APPROACHES TO THE TREATMENT OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
    GRIGG, AP
    BONE MARROW TRANSPLANTATION, 1993, 12 (05) : 431 - 435
12345